Noopept (omberacetam; GVS-111) vs semax
updated
Noopept (omberacetam; GVS-111) (tier B) vs semax (tier B): what each is, why each got its grade, half-life and source counts side by side.
Noopept (omberacetam; GVS-111) · tier B
omberacetam, a small-molecule cognitive drug sold as a registered 10 mg oral tablet in Russia. the cited human signal comes from one small patient comparison, not a healthy-user trial.
tier rationale
B-tier reflects a current foreign registration, one small positive active-comparator patient study, and direct but sparsely reported human pharmacokinetics. It stays below A because the clinical study had no placebo or healthy-user group, long-term healthy-user safety is absent, and US supplement identity is a separate unresolved problem.
semax · tier B
russian nootropic. approved there, not here. for focus, stroke recovery, and cognitive decline. real mechanism, thin US trials.
tier rationale
B-tier because the evidence base is real but geographically and linguistically constrained. Russian regulatory approval for three indications, two decades of clinical use, confirmed BDNF mechanism. Held back from A-tier because Western clinical replication is limited and most primary literature requires Russian-language fluency to read. FDA's 503A process could change the U.S. compounding lane, but that would not be drug approval.
at a glance
| Noopept (omberacetam; GVS-111) | semax | |
|---|---|---|
| tier | B | B |
| category | nootropic / longevity | nootropic / longevity |
| sources | 12 | 26 |
| claims evaluated | 3 | 6 |
| half-life | 22.05 plus or minus 14.37 minutes in a sparsely reported human conference abstract | minutes in plasma; effects persist for hours due to CNS penetration and BDNF induction cascade |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.